ALKERMES | ALKS - Equity Capital And Reserves


ALKERMES reported $1.73B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
ALKERMES USD 1.73B 108.85M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
J&J USD 78.47B 0 Sep/2025
Malin Corporation EUR 193.2M 75M Dec/2024
Merck USD 51.85B 2.79B Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Otsuka Holdings JPY 2.86T 136.72B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 30.96B 1.02B Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025